Compound: mifepristone
SMILES: O=C1C=C2C(=C3[C@@H](c4ccc(N(C)C)cc4)C[C@@]5([C@](O)(C#CC)CC[C@H]5[C@@H]3CC2)C)CC1
InChIKey: VKHAHZOOUSRJNA-GCNJZUOMSA-N
Synonyms: mifepristone, 84371-65-3, Mifegyne, Mifeprex, RU-486, Korlym, RU 486, Mifepristona, RU 38486, RU-38486, Mifepristonum, DTXSID5023322, 320T6RNW1F, NSC-759862, DTXCID303322, CHEBI:50692, (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one, 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE, Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-, ZK98296, NSC652104, R38486, (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta(a)phenanthren-3-one, 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA(A)PHENANTHREN-3-ONE, RU38486, ZK 98296, RefChem:55643, Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11beta,17beta)-, G03XB01, 11-((4-dimethylamino) phenyl)-17-Hydroxy-17-(1-propynyl) Estra-4,9-dien-3-one, (10S,11S,14S,15S,17R)-17-(4-(dimethylamino)phenyl)-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo(8.7.0.02,7.011,15)heptadeca-1,6-dien-5-one, (aa Beta, 17 beta)-11-(4-(dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, 11 Beta-(4-(N,N-dimethylamino)phenyl)-17alpha-(propyl-1-ynyl)-delta-4,9-estradiene-17 beta-ol-3-one, Corlux, RU486, Mifepriston, C29H35NO2, (11beta,17beta)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one, Mifepristone (Standard), MLS000069785, VGX-410C, VGX-410, NCGC00025179-05, SMR000058481, Mifepristonum [Latin], MFCD00867226, Mifepristona [Spanish], (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one, (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one, (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one, (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one, (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-6,7,8,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one, RU486 (tetramethyl-rhodamine conjugated), Mifepristone [USAN:INN:BAN], HSDB 6841, SR-01000076011, R 38486, BRN 5779404, UNII-320T6RNW1F, Pictovir, RU 486-6, CCRIS 9332, 1nhz, 11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, Mifeprex (TN), Pictovir (TM), Prestwick_570, CAS-84371-65-3, Korlym (TN), 2w8y, Mifepristone (Mifeprex), Opera_ID_562, Mifepristone, >=98%, Prestwick0_000299, Prestwick1_000299, Prestwick2_000299, Prestwick3_000299, Spectrum5_002045, MIFEPRISTONE [MI], MIFEPRISTONE [INN], MIFEPRISTONE [JAN], MIFEPRISTONE [HSDB], MIFEPRISTONE [USAN], 11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on, 17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one, MIFEPRISTONE [VANDF], BIDD:PXR0123, Lopac0_000801, SCHEMBL16087, BSPBio_000238, MIFEPRISTONE [MART.], 11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on, 11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one, MLS001074115, MLS001424271, MIFEPRISTONE [USP-RS], MIFEPRISTONE [WHO-DD], SPBio_002457, RU-486; MIFEPRISTONE, BPBio1_000262, CHEMBL438575, GTPL2805, Mifepristone (JAN/USAN/INN), orb3032958, CHEMBL1276308, BDBM18627, MSK8539, GLXC-05981, HMS1568L20, HMS2052L05, HMS2090L22, HMS2095L20, HMS2230P21, HMS3262B03, HMS3412D17, HMS3649J08, HMS3676D17, HMS3712L20, HMS3884D12, MIFEPRISTONE [ORANGE BOOK], ALBB-038643, Tox21_110952, Tox21_301841, Tox21_500801, BDBM50072024, EBC-06067, HB2783, HSCI1_000369, HY-13683R, MSK8539-100A, s2606, VX-410, AKOS015895416, MSK8539-1000A, Tox21_110952_1, CCG-101164, CI-1073, CS-1435, DB00834, FM26002, LP00801, NC00414, NSC 759862, SDCCGSBI-0050778.P002, Mifepristone 1.0 mg/ml in Acetonitrile, NCGC00025179-06, NCGC00025179-07, NCGC00025179-08, NCGC00025179-09, NCGC00025179-12, NCGC00025179-13, NCGC00025179-23, NCGC00179632-01, NCGC00255152-01, NCGC00261486-01, (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one, (1S,3aS,3bS,10R,11aS)-10-[4-(dimethylamino)phenyl]-1-hydroxy-11a-methyl-1-(prop-1-yn-1-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-7-one, AS-13938, CPD000058481, HY-13683, RU486;C-1073, SY077658, CS-0694789, EU-0100801, A11615, C-1073, C07652, D00585, EN300-117256, M 8046, Mifepristone Solution in Acetonitrile, 100ug/mL, Mifepristone Solution in Acetonitrile, 1000ug/mL, Q411240, SR-01000721888, SR-01000076011-1, SR-01000076011-3, SR-01000076011-5, SR-01000076011-9, SR-01000721888-4, BRD-K37270826-001-04-5, BRD-K37270826-001-26-8, BRD-K37270826-001-27-6, BRD-K37270826-001-31-8, Z1501480424, Mifepristone, United States Pharmacopeia (USP) Reference Standard, 11.beta.-[4-(Dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, 11b-(4-Dimethyl-amino)-phenyl-17b-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one, 11beta-(4-Dimethylamino)phenyl-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, 11ss-[p-(Dimethylamino)fenyl]-17ss-hydroxy- 17-(1-propynyl)estra-4,9-dien-3-on, (11|_,17|_)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one, (11|A,17|A)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one, (11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one, (1S,3aS,3bS,10R,11aS)-10-[4-(Dimethylamino)phenyl]-1-hydroxy-11a-methyl-1-(prop-1-yn-1-yl)-1,2,3,3a,3b,4,5,8,9,10,11,11a-dodecahydro-7H-cyclopenta[a]phenanthren-7-one, 122742-25-0, 17beta-Hydroxy-11beta-[4-(dimethylamino)-phenyl]-17alpha-(prop-1-ynyl)-estra-4,9-dien-3-one, 83203-42-3, Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)-, (11.beta.,17.beta.)-, Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)-, (11beta,17beta)-, Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-
Theoretical properties:
molecular_formula: C29H35NO2
molecular_weight: 429.6 g/mol
exact_mass: 429.266779359 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 3
heavy_atom_count: 32
topological_polar_surface_area: 40.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Yellow powder
color: Yellow powder
melting_point: 191-196 °C
solubility: Poorly soluble
vapor_pressure: 8.0X10-14 mm Hg at 25 °C /Estimated/
Descriptions:
pubchem: Mifepristone is a 3-oxo-Delta(4) steroid, a tertiary amino compound and an acetylenic compound. It has a role as a hormone antagonist, a contraceptive drug, a synthetic oral contraceptive and an abortifacient. It derives from a hydride of an estrane.
chembl: MIFEPRISTONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Mifepristone, also known by its developmental code name RU-486, is a drug typically used in combination with misoprostol to bring about a medical abortion during pregnancy. This combination is 97% effective during the first 63 days (9 weeks) of pregnancy, and is effective in the second trimester as well. It is also used on its own to treat Cushing's syndrome or in low doses as an emergency contraceptive.
The most common adverse effects include abdominal pain, feeling tired, and vaginal bleeding. Serious side effects may include heavy vaginal bleeding, bacterial infection, and, if pregnant, birth defects. When used, appropriate follow-up care needs to be available. Mifepristone is primarily an antiprogestogen. It works by blocking the effects of progesterone, making both the cervix and uterine vessels dilate and causing uterine contraction. Mifepristone also works, to a lesser extent, as an antiglucocorticoid and diminishes the effects of hypercortisolism.
Mifepristone was developed in France in 1980 and came into use there in 1987. It became available in the United States in 2000, for medication abortion, and in 2010, for Cushing's syndrome. It is on the World Health Organization's List of Essential Medicines. Mifepristone was approved in China in 1988, India in 2002, and Canada in 2017.